Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Dapsone Topical Gel Co-administered with Adapalene or Benzoyl Peroxide in Acne Vulgaris
NCT00151541Phase 3Completed
- Sponsor
- Allergan
- Start
- Feb 2005
- Primary completion
- Jul 2005
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of dapsone in acne vulgaris (3 arms), sponsored by Allergan. Primary endpoint: Mean percent reduction in inflammatory lesion counts at 12 weeks. Started Feb 2005; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT00151541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151541.